Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2-negative breast cancer

Cancer Commun (Lond). 2023 Aug;43(8):943-946. doi: 10.1002/cac2.12447. Epub 2023 Jun 6.

Authors

François Bertucci^{1

2}, Alexandre De Nonneville^{1

2}, Pascal Finetti¹, Emilie Mamessier¹

Affiliations

¹ Laboratory of Predictive Oncology, Label Team "Ligue contre le cancer", Cancer Research Center of Marseille, Paoli-Calmettes Institute, Aix-Marseille University, Inserm UMR1068, CNRS UMR725, Marseille, France.
² Department of Medical Oncology, Paoli-Calmettes Institute, Marseille, France.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Breast Neoplasms* / drug therapy
Female
Humans
Neoadjuvant Therapy
Receptor, ErbB-2
Tertiary Lymphoid Structures*
Treatment Outcome

Substances

Receptor, ErbB-2